Merck Settles Class Suit Targeting Coppertone Claims, Denies Wrongdoing
This article was originally published in The Rose Sheet
Merck agrees to pay a maximum of $10 million to consumers to settle class-action litigation. Firm’s compliance with sunscreen labeling and claims requirements that will become law in December under an FDA final rule satisfies plaintiffs, who took issue with past Coppertone claims that allegedly overstated products’ sun-protective benefits. The settlement in federal court resolves separate litigation against Coppertone filed in California state court.
You may also be interested in...
A New Jersey-based suit seeking class action certification alleges Merck has misrepresented the UV-protective benefits of its Coppertone sunscreen products, subjecting consumers to potential risks.
FDA pushes back deadlines for compliance with its final rule for sunscreen labeling and effectiveness testing, giving manufacturers an additional six months for products with annual sales of at least $25,000. More news in brief.
Seven of 10 CBD-containing supplement products tested in a lab did not contain the levels of CBD advertised on the label, says hemp, CBD and natural health product information publisher Remedy Reviews. Most products also were found to contain heavy metals.